{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:06:15Z","timestamp":1792854375573,"version":"4.5.0"},"reference-count":19,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2021,10,25]]},"DOI":"10.1253\/circj.cj-20-1051","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T22:07:07Z","timestamp":1620770827000},"page":"2063-2070","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects\u3000\u2015 A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial \u2015"],"prefix":"10.1253","volume":"85","author":[{"given":"Anthony C.","family":"Keech","sequence":"first","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, Sydney Medical School, University of Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Oyama","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School"},{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minao","family":"Tang","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lu","sequence":"additional","affiliation":[{"name":"Amgen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Tay","sequence":"additional","affiliation":[{"name":"Cardiology Department, Changi General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash C.","family":"Deedwania","sequence":"additional","affiliation":[{"name":"University of California San Francisco School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wah","family":"Siu","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Lira Pineda","sequence":"additional","affiliation":[{"name":"Amgen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ji","family":"Charng","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Taipei Veterans General Hospital"},{"name":"Faculty of Medicine, School of Medicine, National Yang Ming University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Amerena","sequence":"additional","affiliation":[{"name":"Geelong Cardiology Research Unit, Barwon Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Azman","family":"Wan Ahmad","sequence":"additional","affiliation":[{"name":"Cardiology Department, University Malaya Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Chopra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Max Super Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje R.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Medical Faculty, Oslo University Hospital Aker"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the FOURIER Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chidambaran V, Ngamprasertwong P, Vinks AA, Sadhasivam S. Pharmacogenetics and anesthetic drugs. <i>Curr Clin Pharmacol<\/i> 2012; 7: 78\u2013101.","DOI":"10.2174\/157488412800228866"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. <i>Pharmacotherapy<\/i> 2007; 27: 874\u2013887.","DOI":"10.1592\/phco.27.6.874"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wang Y, Yan BP, Tomlinson B, Lee VW. Is lipid goal one-size-fits-all: A review of evidence for recommended low-density lipoprotein treatment targets in Asian patients. <i>Eur J Prev Cardiol<\/i> 2019; 26: 1496\u20131506.","DOI":"10.1177\/2047487319843077"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Liao JK. Safety and efficacy of statins in Asians. <i>Am J Cardiol<\/i> 2007; 99: 410\u2013414.","DOI":"10.1016\/j.amjcard.2006.08.051"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. <i>Lancet<\/i> 2005; 366: 1267\u20131278.","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. <i>N Engl J Med<\/i> 2014; 370: 1809\u20131819.","DOI":"10.1056\/NEJMoa1316222"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: Insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>J Am Heart Assoc<\/i> 2017; 6: e006901.","DOI":"10.1161\/JAHA.117.006901"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. <i>J Am Coll Cardiol<\/i> 2014; 63: 2531\u20132540.","DOI":"10.1016\/j.jacc.2014.03.018"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. <i>N Engl J Med<\/i> 2017; 376: 1713\u20131722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. <i>N Engl J Med<\/i> 2018; 379: 2097\u20132107.","DOI":"10.1056\/NEJMoa1801174"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis<\/i> 2019; 290: 140\u2013205.","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol<\/i> 2019; 73: e285\u2013e350.","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) Guidelines for prevention of atherosclerotic cardiovascular diseases 2017. <i>J Atheroscler Thromb<\/i> 2018; 25: 846\u2013984.","DOI":"10.5551\/jat.GL2017"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. <i>Am Heart J<\/i> 2016; 173: 94\u2013101.","DOI":"10.1016\/j.ahj.2015.11.015"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): Scale development and psychometric properties. <i>Neuropsychology<\/i> 2008; 22: 531\u2013544.","DOI":"10.1037\/0894-4105.22.4.531"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gencer B, Mach F, Guo J, Im K, Ruzza A, Wang H, et al. Cognition after lowering LDL-Cholesterol with evolocumab. <i>J Am Coll Cardiol<\/i> 2020; 75: 2283\u20132293.","DOI":"10.1016\/j.jacc.2020.03.039"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive function in a randomized trial of evolocumab. <i>N Engl J Med<\/i> 2017; 377: 633\u2013643.","DOI":"10.1056\/NEJMoa1701131"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Johnson JA. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. <i>Circulation<\/i> 2008; 118: 1383\u20131393.","DOI":"10.1161\/CIRCULATIONAHA.107.704023"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. <i>Lancet<\/i> 2005; 366: 1267\u20131278.","DOI":"10.1016\/S0140-6736(05)67394-1"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/85\/11\/85_CJ-20-1051\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:27:01Z","timestamp":1715142421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/85\/11\/85_CJ-20-1051\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-20-1051","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"article-number":"CJ-20-1051"}}